P14 | DARATUMUMAB-BORTEZOMIB-MELPHALAN-PREDNISONE VS. DARATUMUMAB-LENALIDOMIDE-DEXAMETHASONE IN TRANSPLANT-INELIGIBLE REAL-LIFE PATIENTS WITH MULTIPLE MYELOMA: A SUBANALYSIS OF THE PHASE IV REAL MM TRIAL

Background. Daratumumab-bortezomib-melphalan-prednisone (DVMP) and daratumumab-lenalidomide-dexamethasone (DRd) are standard treatments for transplant-ineligible (NTE) newly diagnosed multiple myeloma (NDMM) patients (pts). No prospective randomized trial has directly compared DVMP vs DRd. Moreover...

詳細記述

書誌詳細

主要な著者:	L. Cani, S. Bringhen, A. Piciocchi, N. Giuliani, S. Mangiacavalli, A.P. Falcone, G. Benevolo, M. Capriata, F. Vassallo, F. Ciceri, F. Pane, R. Floris, M. Cantonetti, S. Pezzatti, M. D'Agostino, A. Casson, A. Evangelista, E. Saraci, M. Mirabile, B. Gamberi, A. Conconi, G. Pietrantuono, P. Galieni, P. Curci, G. Margiotta-Casaluci, A. Liso, M. Scaldaferri, B. Bruno, M. Boccadoro, A. Larocca
フォーマット:	Artigo
言語:	Inglês
出版事項:	Ferrata Storti Foundation 2026-04-01
シリーズ:	Haematologica
オンライン･アクセス:	https://haematologica.org/article/view/14052
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!